ArticleMetabolic brain disease2025
Protective effects of omega-3 against procarbazine-induced brain damage in the cerebellum and CA1 Hippocampus of male rats: a focus on oxidative stress mechanisms.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The study examined the combined effects of procarbazine (PCZ) and omega-3 on cognitive functions, motor skills, and brain histology in male rats over ten days. While PCZ has antitumor properties, omega-3 is a dietary supplement with potential health benefits. Here, forty-eight adult male Wistar rats, averaging 230 to 250 g, were used in this study. Novel Object Recognition (NOR), Open Field Tests (OFT), and rotarod assessments were employed to evaluate cognitive and motor functions. Also, cell degeneration in pyramidal cells of the CA1 region and Purkinje cells in the cerebellum, along with measuring serum oxidant and antioxidant levels to gauge treatment impact on brain functions. Results showed significant weight loss in PCZ-treated rats, alongside fewer rearing instances and reduced distance traveled in OFT compared to the sham group (P < 0.05). However, cognitive performance in the NOR test remained unchanged. The PCZ group demonstrated lower rotarod performance than the sham group (P < 0.05), but the PCZ + omega-3 group showed improved balance. Antioxidant enzyme levels decreased in the PCZ group relative to the sham group (P < 0.05), with no significant change in malondialdehyde levels; omega-3 did not influence these levels in PCZ-treated rats. PCZ caused damage to pyramidal cells in the hippocampus and cerebellum, but omega-3 mitigated some of the cerebellar damage, suggesting it may partially reduce PCZ-induced toxicity. These findings suggest omega-3 could alleviate some negative effects of PCZ on brain functions, especially in the cerebellum.
Indexed as
Identifiers
40088343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.